Aytu Biopharma (AYTU) Sidoti Micro-Cap Virtual Conference summary

Strategic focus and business transformation

• Shifted to a prescription-only business, exiting consumer health and R&D to drive near-term shareholder value.

• Sold the consumer health segment, eliminating cash burn and focusing on profitable prescription assets.

• Prescription segment has been EBITDA positive for 7 of the last 8 quarters, with trailing 12-month adjusted EBITDA over $15 million.

• Reduced SG&A, sales, marketing, and R&D expenses, improving operating leverage.

• Strategic refinancing extended debt maturity to 2028, reducing financial risk and removing going concern language.

Revenue growth and market positioning

• Prescription revenues grew from $60+ million in 2022 to nearly $74 million, driven by ADHD brands.

• ADHD market is large and growing, with 83+ million annual prescriptions and $20+ billion in sales.

• ADHD product prescriptions increased to 35,000+ monthly, with further growth expected in back-to-school season.

• Multivitamin and antihistamine products serve niche pediatric and regional markets, with plans to regain lost formulary coverage.

• No product shortages, enabling capture of market share during competitor supply disruptions.

Product and patient access innovation

• Core ADHD products, Adzenys XR-ODT and Cotempla XR-ODT, are the only extended-release orally disintegrating tablets in the market.

• Clinical data shows rapid symptom improvement and academic performance benefits for patients.

• RxConnect program ensures predictable, affordable access for patients, with most paying no more than $50 copay.

• Over 85% of prescriptions run through RxConnect partner pharmacies, providing high channel visibility and retention.

• RxConnect is scalable, supporting additional brands and enhancing value for both patients and physicians.